FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885335871> ?p ?o ?g. }

• W2885335871 abstract "Inhibition of protein phosphatase 2A (PP2A) tumor suppressor is essential for chronic myelogenous leukemia (CML) stem cell (LSC) maintenance and disease development. Persistence of drug-resistant quiescent LSCs depends on cell-autonomous and bone marrow (BM) signals. Herein, we identified miR-300 as an miRNA inhibited in CD34+ CML progenitors and during blastic transformation (BC) through the BCR-ABL1-dependent inhibition of C/EBPβ-induced miR-300 transcription. In CML progenitors, ectopic mir-300 expression directly targets the PP2A inhibitory pathway (i.e., Jak2, hnRNPA1, SET) and other factors essential for LSC maintenance and disease progression (e.g., CCND1/2, b-catenin, Myc, Twist-1). In leukemic but not normal CD34+ cells, miR-300 acts as a potent tumor suppressor by inducing cell cycle exit and promoting apoptosis. Conversely, hypoxia-induced BCR-ABL1 inhibition and induction of C/EBPβ were found essential for increased miR-300 levels in quiescent LSCs, although mesenchymal stromal cells (MSC)-derived exosomal miR-300 also contributed to it. Moreover, low O2 levels and MSC-derived exosomes induced quiescence of CD34+ CML cells. Notably, expression of an anti-miR-300 in MSCs prevented exosome-induced CD34+ CML growth arrest. LSCs escaped miR-300-induced apoptosis through the autocrine/paracrine TGFβ1-induced expression of TUG1, a lncRNA acting as an miR-300 sponge. In fact, TUG1 or TGFβ1 inhibition decreased quiescent (CFSEMAX) LSC number. By contrast, miR-300 inhibition did not alter LSC survival/self-renewal, further supporting a role for TUG1 as an miR-300 sponge. Accordingly, TUG1 was markedly induced in CFSEMAX but not dividing CD34+ CML cells. In fact, low levels of ectopic miR-300 induced growth arrest (decreased LTC-IC and CFC/replating activity) without affecting quiescent LSC number. By contrast, high doses of miR-300 but not scramble CpG-ODN impaired LSC survival (LTC-IC) and self-renewal (CFC/replating), induced marked killing of quiescent LSCs and dividing progenitors, and impaired CML engraftment in NRG-SGM3 mice. Such effects were further enhanced when CPG-miR-300 and CPG-anti-TUG1 were combined. By contrast, high CpG-miR-300 levels did not affect normal CD34+ cell survival/self-renewal likely because of high TUG1 expression. Altogether our results indicate that while miR-300 loss is essential for survival/proliferation of leukemic progenitors, increased miR-300 levels are required for LSC maintenance. Thus, induction of TUG1 may occur to preserve LSC survival in the BM endosteal niche where quiescence is induced by MSCs and low O2 levels through abnormal miR-300 induction. Thus, disrupting the miR-300/TUG1 balance may represent a potential therapeutic approach for treatment/eradication of LSC-derived leukemias. This work is supported in part by NIH-NCI R01CA163800. Citation Format: Giovannino Silvestri, Lorenzo Stramucci, Justin Ellis, Jason Harb, Paolo Neviani, Bin Zhang, Klara Srutova, Gabriel Pineda, Catriona Jamieson, Bruno Calabretta, Fabio Stagno, Paolo Vigneri, Georgios Nteliopoulos, Philippa May, Alistar Reid, Ramiro Garzon, Denis-Claude Roy, Martin Guimond, Peter Hokland, Michael Deininger, Garrett Fitzgerald, Chris Harman, Francesco Dazzi, Dragana Milojkovic, Jane Apperley, Guido Marcucci, Jianfei Qi, Katerina Machova-Polakova, Xiaoxuan Fan, Maria Baer, Rossana Trotta, Danilo Perrotti. The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1134." @default.
• W2885335871 created "2018-08-22" @default.
• W2885335871 creator A5009994866 @default.
• W2885335871 creator A5017390964 @default.
• W2885335871 creator A5019471904 @default.
• W2885335871 creator A5021188246 @default.
• W2885335871 creator A5021706233 @default.
• W2885335871 creator A5022067885 @default.
• W2885335871 creator A5022081533 @default.
• W2885335871 creator A5024259730 @default.
• W2885335871 creator A5025108971 @default.
• W2885335871 creator A5030193536 @default.
• W2885335871 creator A5031953045 @default.
• W2885335871 creator A5032658855 @default.
• W2885335871 creator A5041829729 @default.
• W2885335871 creator A5043599930 @default.
• W2885335871 creator A5044243669 @default.
• W2885335871 creator A5044469416 @default.
• W2885335871 creator A5046881277 @default.
• W2885335871 creator A5048205983 @default.
• W2885335871 creator A5049910941 @default.
• W2885335871 creator A5050093487 @default.
• W2885335871 creator A5052348906 @default.
• W2885335871 creator A5052835239 @default.
• W2885335871 creator A5056314507 @default.
• W2885335871 creator A5056803476 @default.
• W2885335871 creator A5060959458 @default.
• W2885335871 creator A5061158509 @default.
• W2885335871 creator A5061733081 @default.
• W2885335871 creator A5074115908 @default.
• W2885335871 creator A5078324992 @default.
• W2885335871 creator A5079785741 @default.
• W2885335871 creator A5086020780 @default.
• W2885335871 creator A5088517445 @default.
• W2885335871 date "2018-07-01" @default.
• W2885335871 modified "2023-09-30" @default.
• W2885335871 title "Abstract 1134: The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance" @default.
• W2885335871 doi "https://doi.org/10.1158/1538-7445.am2018-1134" @default.
• W2885335871 hasPublicationYear "2018" @default.
• W2885335871 type Work @default.
• W2885335871 sameAs 2885335871 @default.
• W2885335871 citedByCount "0" @default.
• W2885335871 crossrefType "proceedings-article" @default.
• W2885335871 hasAuthorship W2885335871A5009994866 @default.
• W2885335871 hasAuthorship W2885335871A5017390964 @default.
• W2885335871 hasAuthorship W2885335871A5019471904 @default.
• W2885335871 hasAuthorship W2885335871A5021188246 @default.
• W2885335871 hasAuthorship W2885335871A5021706233 @default.
• W2885335871 hasAuthorship W2885335871A5022067885 @default.
• W2885335871 hasAuthorship W2885335871A5022081533 @default.
• W2885335871 hasAuthorship W2885335871A5024259730 @default.
• W2885335871 hasAuthorship W2885335871A5025108971 @default.
• W2885335871 hasAuthorship W2885335871A5030193536 @default.
• W2885335871 hasAuthorship W2885335871A5031953045 @default.
• W2885335871 hasAuthorship W2885335871A5032658855 @default.
• W2885335871 hasAuthorship W2885335871A5041829729 @default.
• W2885335871 hasAuthorship W2885335871A5043599930 @default.
• W2885335871 hasAuthorship W2885335871A5044243669 @default.
• W2885335871 hasAuthorship W2885335871A5044469416 @default.
• W2885335871 hasAuthorship W2885335871A5046881277 @default.
• W2885335871 hasAuthorship W2885335871A5048205983 @default.
• W2885335871 hasAuthorship W2885335871A5049910941 @default.
• W2885335871 hasAuthorship W2885335871A5050093487 @default.
• W2885335871 hasAuthorship W2885335871A5052348906 @default.
• W2885335871 hasAuthorship W2885335871A5052835239 @default.
• W2885335871 hasAuthorship W2885335871A5056314507 @default.
• W2885335871 hasAuthorship W2885335871A5056803476 @default.
• W2885335871 hasAuthorship W2885335871A5060959458 @default.
• W2885335871 hasAuthorship W2885335871A5061158509 @default.
• W2885335871 hasAuthorship W2885335871A5061733081 @default.
• W2885335871 hasAuthorship W2885335871A5074115908 @default.
• W2885335871 hasAuthorship W2885335871A5078324992 @default.
• W2885335871 hasAuthorship W2885335871A5079785741 @default.
• W2885335871 hasAuthorship W2885335871A5086020780 @default.
• W2885335871 hasAuthorship W2885335871A5088517445 @default.
• W2885335871 hasBestOaLocation W28853358711 @default.
• W2885335871 hasConcept C10205521 @default.
• W2885335871 hasConcept C16930146 @default.
• W2885335871 hasConcept C170493617 @default.
• W2885335871 hasConcept C198826908 @default.
• W2885335871 hasConcept C201750760 @default.
• W2885335871 hasConcept C203014093 @default.
• W2885335871 hasConcept C28328180 @default.
• W2885335871 hasConcept C502942594 @default.
• W2885335871 hasConcept C54355233 @default.
• W2885335871 hasConcept C55493867 @default.
• W2885335871 hasConcept C7876069 @default.
• W2885335871 hasConcept C81885089 @default.
• W2885335871 hasConcept C86803240 @default.
• W2885335871 hasConcept C95444343 @default.
• W2885335871 hasConcept C97037327 @default.
• W2885335871 hasConceptScore W2885335871C10205521 @default.
• W2885335871 hasConceptScore W2885335871C16930146 @default.
• W2885335871 hasConceptScore W2885335871C170493617 @default.
• W2885335871 hasConceptScore W2885335871C198826908 @default.
• W2885335871 hasConceptScore W2885335871C201750760 @default.
• W2885335871 hasConceptScore W2885335871C203014093 @default.
• W2885335871 hasConceptScore W2885335871C28328180 @default.
• W2885335871 hasConceptScore W2885335871C502942594 @default.
• W2885335871 hasConceptScore W2885335871C54355233 @default.

• next